Have you ever seen a water-fall plot looking like a lake before? If you attended this year’s Presidential Session, you did, if not: check the amazing results of the NICHE-2 study in deficient DNA mismatch repair (dMMR) colorectal cancer.
Precision medicine provides a new option in intrahepatic cholangiocarcinoma: mFGFR2 carriers achieve significant benefits with a new, highly selective FGFR inhibitor.
Sip a “Bellini” while going through the same-named study: a high percentage of tumour infiltrating lymphocytes (TILs) is predictive of good neoadjuvant response with checkpoint blockade.
Sacituzumab govitecan may be the new standard for HR-positive HER2-negative advanced breast cancer refractory to hormonal treatment.
Also, there is amazing news in melanoma treatment: Just 3 neoadjuvant cycles can make the difference in recurrence-free survival, according to a study comparing purely adjuvant versus neoadjuvant/adjuvant pembrolizumab, in resectable stage III and IV melanoma patients.
…and reinfusing harvested and in-vitro expanded tumour infiltrating lymphocytes outperforms 2nd line checkpoint inhibition in metastatic melanoma patients.
And please check out Charles Swanton’s fantastic presentation of the pathogenesis from air pollution to lung cancer: a milestone event.
As always, you’ll find all of the above in detail below, and there’s a lot more to digest.
I hope you enjoy our ESMO 2022 congress report.
Dr Stefan Rauh is currently working as haematooncologist in the oncology department of the Centre Hospitalier Emile Mayrisch, Esch, Luxembourg. He is mainly involved in clinical work but also in research and teaching activities and is interested in public policy and international cooperation projects in oncology. He is member of the ESMO Practicing Oncologist’s Working Group since 2011 (chair 2014-2018) and the ESMO Public Policy Committee, and has been an ESMO Executive Board member in 2015-2016. He is co-author of the 2017 ESMO European Cancer Patient Coalition (ECPC) Patient Survivorship Guide and an invited expert for the ECPC.
Conflict of Interest Statement: Nothing to declare.
« Adding first-line pembrolizumab to CRT in locally advanced HNSCC does not significantly prolong survival or event-free survival Next Article
Type 2 inflammatory diseases in paediatric patients with atopic dermatitis »
Table of Contents: ESMO 2022
Letter from the Editor
High pathological responses to neoadjuvant immune checkpoint inhibition in locally advanced dMMR colon cancer
Fruquintinib: a potential new treatment for patients with refractory mCRC
Second-line avelumab is effective in patients with MSI-H/dMMR mCRC
Upper Gastrointestinal Cancer
Deep learning models predict the risk of relapse and the mutational profile in GIST
Addition of pembrolizumab to lenvatinib does not improve OS in advanced HCC
New, highly selective inhibitor of FGFR2 driver alterations and resistance mutations
Chemo-immunotherapy in gastric cancer is more effective when administered in parallel
Tumour infiltrating lymphocytes identify patients with immunogenic triple-negative breast cancer
OS benefit of abemaciclib in HR-positive/HER2-negative advanced breast cancer not (yet) statistically significant
OS benefit of sacituzumab govitecan in pre-treated HR-positive/HER2-negative metastatic breast cancer
A pathway from air pollution to lung cancer in non-smokers identified
Selective KRASG12C inhibitor sotorasib demonstrates superior PFS and ORR compared to docetaxel in previously treated patients with NSCLC
Promising clinical activity of tepotinib plus osimertinib in NSCLC with MET amplification after progression on first-line osimertinib
High pathological responses in borderline resectable NSCLC patients after induction with dual immunotherapy and concurrent chemoradiotherapy
Treatment with tumour-infiltrating lymphocytes for advanced melanoma outperforms ipilimumab
Neoadjuvant pembrolizumab outperforms adjuvant pembrolizumab in resectable stage III–IV melanomas
Survival-benefit of neoadjuvant T-VEC maintained over 5 years of follow-up
Baseline ctDNA predicts survival in resected stage III–IV melanoma
Genitourinary Cancer – Prostate Cancer
Overall survival benefit of abiraterone in mHSPC is maintained for 7 years
Limited benefit of adding long-term ADT to post-operative radiotherapy in prostate cancer
Intensified ADT benefits biochemical progression-free survival in biochemically relapsed prostate cancer
Genitourinary Cancer – Non-Prostate Cancer
Adjuvant nivolumab plus ipilimumab does not improve survival in patients with localised RCC at high risk of relapse after nephrectomy
Triple therapy improves progression-free survival in patients with advanced RCC versus dual therapy
Adjuvant atezolizumab does not improve outcomes for patients with RCC and increased risk of recurrence
OS benefit for advanced ovarian cancer patients treated with maintenance olaparib
Maintenance tegafur-uracil does not improve survival in locally advanced cervical cancer
Head and Neck Cancer
Adding first-line pembrolizumab to CRT in locally advanced HNSCC does not significantly prolong survival or event-free survival
5-FU-free chemotherapy combination as an alternative for first-line treatment of recurrent or metastatic HNSCC
Epstein Barr virus-specific autologous cytotoxic T lymphocytes do not improve survival in nasopharyngeal carcinoma